AptarGroup, Inc. (ATR) Earnings Call Analysis

NYSE · Healthcare · Medical Instruments & Supplies

19/25

Growth 2 Margin 4 Expansion 5 Platform 4 Financial 4

latest quarter score

Earnings Reports

19
Aptar (ATR) Q2 2026: Pharma Ex-Emergency Grows 8%, Margin Recovery Signals Inflection
July 31, 2026
17
Aptar (ATR) Q4 2025: Tooling Sales Hit Decade High, Margin Headwinds Set Stage for 2026 Reset
June 15, 2026
19
APTAR (ATR) Q1 2026: Emergency Medicine Down $65M, Margin Compression Drives Cautious Optimism
May 01, 2026
17
Aptar (ATR) Q3 2025: Emergency Medicine Set for 35% Decline, Margin Mix Faces Reset
October 31, 2025
23
APTAR (ATR) Q2 2025: Pharma Margin Rises 130bps as Injectables and Active Materials Offset Emergency Med Slowdown
August 01, 2025
25
Aptar (ATR) Q1 2025: EBITDA Margin Expands 120bps as Pharma and Beauty Pipelines Reaccelerate
July 06, 2025
Aptar (ATR) Q3 2024: Pharma Royalty Revenue Grows, Margins Hit 23% High as Closures Rebounds
October 25, 2024
Aptar (ATR) Q2 2024: Pharma Drives 7% Segment Growth as Beauty Normalizes and Capex Peaks
July 26, 2024
APTAR (ATR) Q1 2024: Pharma Core Sales Up 13% as Proprietary Drug Delivery Drives Structural Margin Gains
April 26, 2024
Aptar (ATR) Q4 2023: Pharma Core Sales Up 11% as Margin Expansion Drives Double-Digit EPS Growth
February 09, 2024
Aptar (ATR) Q3 2023: Pharma Segment Delivers 8% Core Sales Growth, Margin Expansion Signals Operating Leverage
October 26, 2023
APTAR (ATR) Q2 2023: Pharma Core Sales Jump 13% as Injectables Rebound Drives Pipeline Visibility
July 28, 2023
Aptar (ATR) Q1 2023: Pharma Devices Propel 7% Segment Surge as ERP Headwinds Fade
April 28, 2023
AptarGroup (ATR) Q4 2022: Pharma Core Sales Up 8% as Segment Realignment Targets Margin Gains
February 17, 2023

Browse all companies